Vancomycin

Vancomycin is a topic covered in the Washington Manual of Medical Therapeutics.

To view the entire topic, please or .

The Washington Manual is an award-winning, complete mobile solution for nurses and students. Look up information on diseases, tests, and procedures; then consult the database with 5,000+ drugs or refer to 65,000+ dictionary terms. Explore these free sample topics:

-- The first section of this topic is shown below --

Treatment

  • Vancomycin (usual starting dose is 15 mg/kg IV q12h) is a glycopeptide antibiotic that interferes with cell wall synthesis by binding to D-alanyl-D-alanine precursors that are critical for peptidoglycan cross-linking in most gram-positive bacterial cell walls. Vancomycin is bactericidal for staphylococci but bacteriostatic for enterococci.
  • Vancomycin-resistant Enterococcus faecium (VRE) and vancomycin intermediate-resistant S. aureus (VISA) present increasing treatment challenges. Vancomycin-resistant S. aureus has been reported but remains rare. Indications for use are listed in Table 15-2.
  • The goal trough concentration is 15–20 μg/mL for treatment of serious infections. Lower troughs of 10–20 μg/mL may be appropriate for less severe infections.
  • Dose adjusting to a target AUC: Minimum inhibitory concentration (MIC) range of 400–600 mg*h/L, assuming an MIC of 1 mg/L, is recommended for the treatment of serious MRSA infections where pharmacokinetic monitoring and adjustments can be provided quickly and reliably.
Table 15-2: Indications for Vancomycin Use
Treatment of serious infections caused by documented or suspected MRSA
Treatment of serious infections caused by ampicillin-resistant, vancomycin-sensitive enterococci
Treatment of serious infections caused by gram-positive bacteria in patients who are allergic to other appropriate therapies
Surgical prophylaxis for placement of prosthetic devices at institutions with known high rates of MRSA or in patients who are known to be colonized with MRSA
Empiric use in suspected gram-positive meningitis until an organism has been identified and sensitivities confirmed
Oral treatment of Clostridioides difficile colitis

MRSA, methicillin-resistant Staphylococcus aureus.

-- To view the remaining sections of this topic, please or --

Treatment

  • Vancomycin (usual starting dose is 15 mg/kg IV q12h) is a glycopeptide antibiotic that interferes with cell wall synthesis by binding to D-alanyl-D-alanine precursors that are critical for peptidoglycan cross-linking in most gram-positive bacterial cell walls. Vancomycin is bactericidal for staphylococci but bacteriostatic for enterococci.
  • Vancomycin-resistant Enterococcus faecium (VRE) and vancomycin intermediate-resistant S. aureus (VISA) present increasing treatment challenges. Vancomycin-resistant S. aureus has been reported but remains rare. Indications for use are listed in Table 15-2.
  • The goal trough concentration is 15–20 μg/mL for treatment of serious infections. Lower troughs of 10–20 μg/mL may be appropriate for less severe infections.
  • Dose adjusting to a target AUC: Minimum inhibitory concentration (MIC) range of 400–600 mg*h/L, assuming an MIC of 1 mg/L, is recommended for the treatment of serious MRSA infections where pharmacokinetic monitoring and adjustments can be provided quickly and reliably.
Table 15-2: Indications for Vancomycin Use
Treatment of serious infections caused by documented or suspected MRSA
Treatment of serious infections caused by ampicillin-resistant, vancomycin-sensitive enterococci
Treatment of serious infections caused by gram-positive bacteria in patients who are allergic to other appropriate therapies
Surgical prophylaxis for placement of prosthetic devices at institutions with known high rates of MRSA or in patients who are known to be colonized with MRSA
Empiric use in suspected gram-positive meningitis until an organism has been identified and sensitivities confirmed
Oral treatment of Clostridioides difficile colitis

MRSA, methicillin-resistant Staphylococcus aureus.

There's more to see -- the rest of this topic is available only to subscribers.